Aroa Biosurgery (ARX) Q4 2025 earnings summary

Executive summary

• Achieved two consecutive quarters of positive operating cash flow, ending with a cash balance of NZ$22 million and remaining debt-free.

• Focused on high-growth soft tissue regeneration, with over 7 million patient treatments and 100+ peer-reviewed publications validating efficacy and safety.

• U.S. market is the primary revenue driver, accounting for over 95% of sales.

• Myriad product family achieved record sales in March 2025 at US$2 million, up 11% sequentially and 32% year-over-year.

• Ovitex sales to TelaBio increased 17% year-over-year; TelaBio reported US$69.3 million in CY2024 revenue, up 19%.

Financial highlights

• Maintained FY25 reported revenue guidance of NZ$81–84 million and normalised EBITDA profit of NZ$2–4 million.

• On a constant currency basis, revenue guidance is NZ$76–79 million and EBITDA up to NZ$2 million.

• Positive operating cash flow of NZ$1.1 million for the quarter; cash receipts totaled NZ$20.1 million.

• Net cash outflow from investing activities was NZ$0.6 million, mainly for routine capital expenditure.

• Remained debt-free with total cash and cash equivalents at NZ$21.99 million at quarter end.

Outlook and guidance

• Revenue and EBITDA guidance for FY25 reaffirmed, with expectations of continued operational profitability and top-line growth.

• Full year financial results to be reported on 27 May 2025.